Urology
Volume 72, Issue 6, Supplement , Pages S12-S24 , December 2008

Evaluating Localized Prostate Cancer and Identifying Candidates for Focal Therapy

  • A. Oliver Sartor

      Affiliations

    • Department of Medicine, Harvard Medical School, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
    • Corresponding Author InformationReprint requests: Oliver Sartor, M.D., Departments of Medicine and Urology, Tulane Cancer Center, New Orleans, LA 70115
    • ,
  • Hedvig Hricak

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, New York, New York
    • ,
  • Thomas M. Wheeler

      Affiliations

    • Baylor College of Medicine, Houston, Texas
    • ,
  • Jonathan Coleman
    • ,
  • David F. Penson

      Affiliations

    • Norris Comprehensive Cancer Center, Los Angeles, California
    • ,
  • Peter R. Carroll

      Affiliations

    • University of California, San Francisco, San Francisco, California
    • ,
  • Mark A. Rubin

      Affiliations

    • Weill Cornell Medical Center, New York, New York
    • ,
  • Peter T. Scardino

      Affiliations

    • Memorial Sloan-Kettering Cancer Center, New York, New York

References 

  1. Eggener SE, Scardino PT, Carroll PR, et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007;178:2260–2267
  2. Gleason DF. Histologic grading and clinical staging of carcinoma of the prostate. In:  Tannenbaum M editors. Urologic Pathology. Philadelphia: Lea & Febiger; 1977;p. 171–198
  3. Anderson PR, Hanlon AL, Patchefsky A, et al. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy. Int J Radiat Oncol Biol Phys. 1998;41:1087–1092
  4. Beard CJ, Chen MH, Cote K, et al. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer. Int J Radiat Oncol Biol Phys. 2004;58:19–24
  5. Freedland SJ, Isaacs WB, Platz EA, et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol. 2005;23:7546–7554
  6. Stamey TA, Caldwell M, McNeal JE, et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol. 2004;172:1297–1301
  7. D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125–135
  8. D'Amico AV, Renshaw AA, Sussman B, et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294:440–447
  9. Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368–374
  10. Goto Y, Ohori M, Arakawa A, et al. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol. 1996;156:1059–1063
  11. Kattan MW, Shariat SF, Andrews B, et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol. 2003;21:3573–3579
  12. van Gils MP, cornel EB, Hessels D, et al. Molecular PCA3 diagnostics on prostatic fluid. Prostate. 2007;67:881–887
  13. Laxman B, Tomlins SA, Mehra R, et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia. 2006;8:885–888
  14. Li R, Heydon K, Hammond ME, et al. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in Radiation Therapy Oncology Group protocol 86-10. Clin Cancer Res. 2004;10:4118–4124
  15. Pollack A, DeSilvio M, Khor LY, et al. Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group trial 92-02. J Clin Oncol. 2004;22:2133–2140
  16. Freedland SJ, de Gregorio F, Sacoolidge JC, et al. Predicting biochemical recurrence after radical prostatectomy for patients with organ-confined disease using p27 expression. Urology. 2003;61:1187–1192
  17. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–648
  18. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol. 2007;20:538–544
  19. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26:4596–4599
  20. Clark J, Merson S, Jhavar S, et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene. 2007;26:2667–2673
  21. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110–114
  22. Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007;69:1095–1101
  23. Blute ML, Bergstralh EJ, Partin AW, et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol. 2000;164:1591–1595
  24. Graefen M, Augustin H, Karakiewicz PI, et al. Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? (A validation study of the Partin tables). Eur Urol. 2003;43:6–11
  25. Penson DF, Grossfeld GD, Li YP, et al. How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? (Results of the Cancer of the Prostate Strategic Urological Research Endeavor). J Urol. 2002;167:1653–1658
  26. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  27. D'Amico AV, Moul J, Carroll PR, et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003;21:2163–2172
  28. D'Amico AV, Whittington R, Malkowicz SB, et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol. 2000;18:1164–1172
  29. Roach M, Lu J, Pilepich MV, et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys. 2000;47:609–615
  30. Mitchell JA, Cooperberg MR, Elkin EP, et al. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol. 2005;173:1126–1131
  31. Tsai HK, Chen MH, McLeod DG, et al. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. Cancer. 2006;107:2597–2603
  32. Cagiannos I, Karakiewicz P, Eastham JA, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol. 2003;170:1798–1803
  33. Koh H, Kattan MW, Scardino PT, et al. A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. J Urol. 2003;170:1203–1208
  34. Ohori M, Kattan MW, Koh H, et al. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol. 2004;171:1844–1849
  35. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766–771
  36. Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000;18:3352–3359
  37. Kattan MW, Potters L, Blasko JC, et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology. 2001;58:393–399
  38. Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol. 2003;21:4568–4571
  39. Graefen M, Karakiewicz PI, Cagiannos I, et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2002;20:3206–3212
  40. Graefen M, Karakiewicz PI, Cagiannos I, et al. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol. 2002;20:951–956
  41. Bianco FJ, Kattan MW, Scardino PT, et al. Radical prostatectomy nomograms in black American men: accuracy and applicability. J Urol. 2003;170:73–77
  42. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006;98:715–717
  43. Zelefsky MJ, Kattan MW, Fearn P, et al. Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Urology. 2007;70:283–287
  44. Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco, Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005;173:1938–1942
  45. Freedland SJ, Terris MK, Csathy GS, et al. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. J Urol. 2004;171:2215–2220
  46. Kattan MW, Cuzick J, Fisher G, et al. A nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer. 2008;112:69–74
  47. Pickles T, Liu M, Berthelet E, et al. The effect of smoking on outcome following external radiation for localized prostate cancer. J Urol. 2004;171:1543–1546
  48. Amling CL. Relationship between obesity and prostate cancer. Curr Opin Urol. 2005;15:167–171
  49. Mallah KN, DiBlasio CJ, Rhee AC, et al. Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy. Cancer. 2005;103:2030–2034
  50. Hall WH, Jani AB, Ryu JK, et al. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis. 2005;8:22–30
  51. Moore RA. The morphology of small prostatic carcinomas. J Urol. 1935;33:224–234
  52. Greene DR, Rogers E, Wessels EC, et al. Some small prostate cancers are nondiploid by nuclear image analysis: correlation of deoxyribonucleic acid ploidy status and pathological features. J Urol. 1994;151:1301–1307
  53. Wise AM, Stamey TA, McNeal JE, et al. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology. 2002;60:264–269
  54. Cheng L, Jones TD, Pan CX, et al. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol. 2005;18:1022–1026
  55. Ohori M. Is focal therapy reasonable in patients with early stage prostate cancer (CaP)—an analysis of radical prostatectomy (RP) specimens (abstract). J Urol. 2006;173:
  56. Villers A, McNeal JE, Freiha FS, et al. Multiple cancers in the prostate: morphologic features of clinically recognized versus incidental tumors. Cancer. 1992;70:2313–2318
  57. Rukstalis DB, Goldknopf JL, Crowley EM, et al. Prostate cryoablation: a scientific rationale for future modifications. Urology. 2002;60(suppl 1):19–25
  58. Noguchi M, Stamey TA, McNeal JE, et al. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol. 2003;170:459–463
  59. McNeal JE, Bostwick DG, Kindrachuck RA, et al. Patterns of progression in prostate cancer. Lancet. 1986;1:60–63
  60. Sakr WA, Haas GP, Cassin BF, et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993;150:379–385
  61. Aihara M, Wheeler TM, Ohori M, et al. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology. 1994;43:60–67
  62. Stamey TA, McNeal JE, Yemoto CM, et al. Biological determinants of cancer progression in men with prostate cancer. JAMA. 1999;281:1395–1400
  63. Rubin MA, Mucci NR, Manley S, et al. Predictors of Gleason pattern 4/5 prostate cancer on prostatectomy specimens: can high grade tumor be predicted preoperatively?. J Urol. 2001;165:114–118
  64. McNeal JE, Haillot O. Patterns of spread of adenocarcinoma in the prostate as related to cancer volume. Prostate. 2001;49:48–57
  65. Epstein JI, Carmichael MJ, Partin AW, et al. Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications. J Urol. 1994;151:1587–1592
  66. Kulkarni GS, Al-Azab R, Lockwood G, et al. Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol. 2006;175:505–509
  67. Hodge KK, McNeal JE, Terris MK, et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 1989;142:71–75
  68. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol. 2002;167:2435–2439
  69. Presti JC, Chang JJ, Bhargava V, et al. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol. 2000;163:163–167
  70. Presti JC, O'Dowd GJ, Miller MC, et al. Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol. 2003;169:125–129
  71. Naughton CK, Ornstein DK, Smith DS, et al. Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores. J Urol. 2000;163:168–171
  72. Singh H, canto EI, Shariat SF, et al. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol. 2004;171:1089–1092
  73. Fleshner N, Rakovitch E, Klotz L. Differences between urologists in the United States and Canada in the approach to prostate cancer. J Urol. 2000;163:1461–1466
  74. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol. 1997;157:199–203
  75. Gore JL, Shariat SF, Miles BJ, et al. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol. 2001;165:1554–1559
  76. Applewhite JC, Matlaga BR, McCullough DL. Results of the 5 region prostate biopsy method: the repeat biopsy population. J Urol. 2002;168:500–503
  77. Obek C, Louis P, Civantos F, et al. Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen. J Urol. 1999;161:494–499
  78. Scherr DS, Eastham J, Ohori M, et al. Prostate biopsy techniques and indications: when, where, and how?. Semin Urol Oncol. 2002;20:18–31
  79. Pelzer A, Bektic J, Berger AP, et al. Prostate cancer detection in men with prostate specific antigen 4-10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. J Urol. 2005;173:1926–1929
  80. Lattouf JB, Grubb RL, Lee SJ, et al. Magnetic resonance imaging-directed transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer. BJU Int. 2007;99:1041–1046
  81. Singh AK, Krieger A, Lattouf JB, et al. Patient selection determines the prostate cancer yield of dynamic contrast-enhanced magnetic resonance imaging-guided transrectal biopsies in a closed 3-Tesla scanner. BJU Int. 2008;101:181–185
  82. Pepe P, Aragona F. Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. Urology. 2007;70:1131–1135
  83. Stewart CS, Leibovich BC, Weaver AL, et al. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol. 2001;166:86–92
  84. Pinkstaff DM, Igel TC, Petrou SP, et al. Systematic transperineal ultrasound-guided template biopsy of the prostate: three-year experience. Urology. 2005;65:735–739
  85. Chon CH, Lai FC, McNeal JE, et al. Use of extended systematic sampling in patients with a prior negative prostate needle biopsy. J Urol. 2002;167:2457–2460
  86. Borboroglu PG, Comer SW, Riffenburgh RH, et al. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol. 2000;163:158–162
  87. Peck S. Transperineal needle biopsy of the prostate. J Urol. 1972;107:1025–1027
  88. Igel TC, Knight MK, Young PR, et al. Systematic transperineal ultrasound guided template biopsy of the prostate in patients at high risk. J Urol. 2001;165:1575–1579
  89. Bott SR, Henderson A, Halls JE, et al. Extensive transperineal template biopsies of prostate: modified technique and results. Urology. 2006;68:1037–1041
  90. Moran BJ, Braccioforte MH, Conterato DJ. Re-biopsy of the prostate using a stereotactic transperineal technique. J Urol. 2006;176:1376–1381
  91. Merrick GS, Gutman S, Andreini H, et al. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol. 2007;52:715–723
  92. Crawford ED, Wilson SS, Torkko KC, et al. Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy. BJU Int. 2005;96:999–1004
  93. Miller J, Perumalla C, Heap G. Complications of transrectal versus transperineal prostate biopsy. ANZ J Surg. 2005;75:48–50
  94. Webb JA, Shanmuganathan K, McLean A. Complications of ultrasound-guided transperineal prostate biopsy: a prospective study. Br J Urol. 1993;72:775–777
  95. Ryan PG, Peeling WB. Perineal prostatic tumour seedling after “Tru-Cut” needle biopsy: case report and review of the literature. Eur Urol. 1990;17:189–192
  96. Wang L, Hricak H, Kattan MW, et al. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology. 2006;238:597–603
  97. Wang L, Mullerad M, Chen HN, et al. Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension. Radiology. 2004;232:133–139
  98. Mullerad M, Hricak H, Wang L, et al. Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology. 2004;232:140–146
  99. Hricak H, Wang L, Wei DC, et al. The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer. 2004;100:2655–2663
  100. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol. 2000;164:400–404
  101. Akin O, Sala E, Moskowitz CS, et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology. 2006;239:784–792
  102. Kitamura Y, Kaji Y, Li H, et al. Prostate cancer derived from transition zone specific findings on MR imaging. Presented at the Ninth European Symposium on Urogenital Radiology, June 15-20, 2002, Genoa, Italy.
  103. Coakley FV, Kurhanewicz J, Lu Y, et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology. 2002;223:91–97
  104. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005;234:804–814
  105. Shukla-Dave A, Hricak H, Kattan MW, et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int. 2007;99:786–793
  106. Parivar F, Hricak H, Shinohara K, et al. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology. 1996;48:594–599
  107. Kalbhen CL, Hricak H, Shinohara K, et al. Prostate carcinoma: MR imaging findings after cryosurgery. Radiology. 1996;198:807–811
  108. Rouviere O, Souchon R, Salomir R, et al. Transrectal high-intensity focused ultrasound ablation of prostate cancer: effective treatment requiring accurate imaging. Eur J Radiol. 2007;63:317–327
  109. Hindley J, Gedroyc WM, Regan L, et al. MRI guidance of focused ultrasound therapy of uterine fibroids: early results. AJR Am J Roentgenol. 2004;183:1713–1719

PII: S0090-4295(08)01732-9

doi: 10.1016/j.urology.2008.10.004

Urology
Volume 72, Issue 6, Supplement , Pages S12-S24 , December 2008

Article Tools

* Image Usage & Resolution